PortViewPortView
Electra Therapeutics logo

Electra Therapeutics (ETRA) Stock Analysis

NASDAQHealthcareMedical - Pharmaceuticals

$8.95+4.99%
1-year price historyRange $8.37 – $13.92
52-week range$8.95
$8.26$15.50

Track ETRA in your portfolio for free · Portfolio tracker

What Electra Therapeutics does

Electra Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in therapies against novel targets for diseases in immunology and cancer. The company was founded by Adam Rosenthal on October 11, 2018 and is headquartered in South San Francisco, CA.

Key metrics

Market cap
$189.75M
P/E (TTM)
-3.38
EPS (TTM)
$-2.65
Beta
0.00
50-day avg
$10.16
200-day avg
$10.16
52-week high
$15.50
52-week low
$8.26
CEO
Quehuong Dong

ETFs linked to ETRA

Broad-market and Healthcare sector ETFs an investor holding Electra Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ETRA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze ETRA in PortView →

Similar companies

Frequently asked questions

What is the ticker symbol for Electra Therapeutics?
Electra Therapeutics trades under the ticker ETRA on NASDAQ.
Which exchange is ETRA listed on?
ETRA is listed on NASDAQ.
What sector does Electra Therapeutics operate in?
Electra Therapeutics is classified in the Healthcare sector (Medical - Pharmaceuticals industry).
How can PortView help analyze ETRA in a portfolio?
PortView shows ETRA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.